title: European mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients.
abstract: OBJECTIVE
  Mitochondria are multifunctional organelles with a key role in the innate immune response against viral infections. Mitochondrial DNA (mtDNA) haplogroups have been related to AIDS progression and CD4 T-cell recovery in HIV-infected patients, and to a delay in the development of liver fibrosis in HIV/hepatitis C virus (HCV)-coinfected patients. We performed a study to investigate whether mtDNA haplogroups may be associated with HCV treatment response in HIV/HCV-coinfected patients on pegylated interferon (pegIFN) plus ribavirin (RBV).
  
  
  METHODS
  We performed a retrospective study in 304 patients who completed a course of HCV therapy. mtDNA polymorphisms were genotyped using Sequenom's MassARRAY platform. The interleukin-28B (IL-28B) polymorphism (rs12980275) was genotyped using the GoldenGate® assay. Sustained virological response (SVR) was defined as an undetectable HCV viral load at week 24 after the end of treatment. The statistical analysis was carried out using on-treatment data.
  
  
  RESULTS
  The SVR rates were 52.6% (160 of 304) for all patients, and 37.8% (46 of 201) for patients with HCV genotype 1 or 4 vs. 81.4% (83 of 102) for patients with HCV genotype 2 or 3 (P < 0.001). No significant associations were found between mtDNA haplogroup and SVR when all patients were included in the analysis and when patients were stratified by HCV genotype (i.e. those with genotypes 1/4 and 2/3 analysed separately) or IL-28B rs12980275 genotype.
  
  
  CONCLUSIONS
  European mtDNA haplogroups were not related to HCV treatment response in HIV/HCV-coinfected patients on pegIFN-α/RBV therapy.
authors.affiliation: HIV/Hepatitis Coinfection Unit, Microbiology National Center, Carlos III Health Institute, Majadahonda, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Guzmán-Fulgencio
authors.forename: N
authors.initials: N
authors.lastname: Rallón
authors.forename: J
authors.initials: J
authors.lastname: Berenguer
authors.forename: A
authors.initials: A
authors.lastname: Fernández-Rodríguez
authors.forename: V
authors.initials: V
authors.lastname: Soriano
authors.forename: P
authors.initials: P
authors.lastname: Miralles
authors.forename: M A
authors.initials: MA
authors.lastname: Jiménez-Sousa
authors.forename: C
authors.initials: C
authors.lastname: Restrepo
authors.forename: J C
authors.initials: JC
authors.lastname: López
authors.forename: M
authors.initials: M
authors.lastname: García-Álvarez
authors.forename: T
authors.initials: T
authors.lastname: Aldámiz
authors.forename: J M
authors.initials: JM
authors.lastname: Benito
authors.forename: S
authors.initials: S
authors.lastname: Resino
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D060085:Coinfection / Q000188:drug therapy; D004272:DNA, Mitochondrial / Q000235:genetics*; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications*; D006239:Haplotypes; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D011994:Recombinant Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use*; D013030:Spain; D044465:White People
chemical_list: D000998:Antiviral Agents; D004272:DNA, Mitochondrial; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a
keywords: AIDS; antiviral therapy; chronic hepatitis C; interferon; mitochondria; polymorphisms